HRMY Harmony Biosciences Holdings, Inc.

Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. Established in 2017 by founder Paragon Biosciences LLC, our mission is to positively impact the lives of those living with rare diseases who are so often underserved.

$35.58  -1.25 (-3.39%)
As of 12/03/2021 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/19/2020
Outstanding shares:  58,471,519
Average volume:  300,450
Market cap:   $2,153,506,045
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    413197104
ISIN:        US4131971040
Sedol:      BKSGZN7
Valuation   (See tab for details)
PE ratio:   178.19
PB ratio:   13.67
PS ratio:   7.96
Return on equity:   7.68%
Net income %:   4.32%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy